


This article was downloaded by: [Tufts University]

On: 10 November 2014, At: 12:53

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn19>

Pyrimidine Nucleotidases/ Phosphotransferases from Human Erythrocyte

A. Amici^a, M. Emanuelli^a, N. Raffaelli^a, S. Ruggieri^b & G. Magni^a

^a Istituto di Biochimica, Università di Ancona, Facoltà di Medicina e Chirurgia, Via Ranieri, 60131, Ancona, Italy

^b Dipartimento di Biotecnologie Agrarie ed Ambientali, Università di Ancona, Via Ranieri, 60131, Ancona, Italy

Published online: 04 Oct 2006.

To cite this article: A. Amici, M. Emanuelli, N. Raffaelli, S. Ruggieri & G. Magni (1999) Pyrimidine Nucleotidases/Phosphotransferases from Human Erythrocyte, *Nucleosides and Nucleotides*, 18:4-5, 853-855, DOI: [10.1080/15257779908041580](https://doi.org/10.1080/15257779908041580)

To link to this article: <http://dx.doi.org/10.1080/15257779908041580>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

PYRIMIDINE NUCLEOTIDASES / PHOSPHOTRANSFERASES FROM HUMAN ERYTHROCYTE

A. Amici, M. Emanuelli, N. Raffaelli, S. Ruggieri§ and G. Magni*

Istituto di Biochimica, Facoltà di Medicina e Chirurgia, §Dipartimento di Biotecnologie Agrarie ed Ambientali, Università di Ancona, Via Ranieri, 60131, Ancona, Italy.

ABSTRACT: Two cytoplasmic pyrimidine 5'-nucleotidase have been purified from human erythrocytes to homogeneity and partially characterized. The two enzymes, indicated as PN-I and PN-II, preferentially hydrolyse pyrimidine 5'-monophosphates and 3'-monophosphates, respectively. The kinetic analysis demonstrate that pyrimidine 5'-nucleotidases, in the presence of suitable nucleoside substrates, can operate as phosphotransferases by transferring phosphate to various nucleoside acceptors, including nucleoside analogues known as important drugs widely used in chemotherapy.

Erythrocyte pyrimidine 5'-nucleotidases specifically catalyze the dephosphorylation of various pyrimidine nucleoside monophosphates to their respective nucleosides. Two activities, called PN-I and PN-II, were identified in the soluble fraction of human erythrocytes on the basis of their different substrate specificities¹. Nucleotidase and phosphotransferase activities were measured by a HPLC-based assay, as previously described², with slight modifications. Alternately the enzyme activity was assayed by measuring the amount of phosphate released. For the measurement of the phosphotransferase activity the incubation mixture contained: 100 mM Tris-HCl pH 7.4, 10 mM MgCl₂, 0.04 mg/ml BSA, 5 μM - 5 mM nucleoside monophosphate donor, 1-40 mM nucleoside acceptor, and an appropriate amount of enzyme to ensure initial rate conditions. After the incubation of 30 min at 37°C, the reaction was terminated by the addition of 0.4M HClO₄ and the mixture, neutralized with 1M K₂CO₃, was analyzed by HPLC, using a C-18 reversed phase (250 x 4.6 mm) column. After equilibration with 0.1 M KH₂PO₄, pH 6.0 buffer, the substrates and the products were separated by a linear gradient of methanol ranging from 0 to 20% in the same buffer.

The two cytoplasmic forms of pyrimidine 5'-nucleotidase have been purified from human erythrocytes to apparent homogeneity and partially characterized in our laboratory³. PN-I and PN-II preferentially hydrolyse pyrimidine 5'-monophosphates and 3'-monophosphates, respectively. It has been also found that PN-I and PN-II are active on nucleoside monophosphate analogues, known as important drugs, like 3'-azido-3'-deoxy-thymidine-5'-monophosphate (AZT-MP), cytosine-β-D-arabinofuranoside-5'-monophosphate (Ara-CMP), and 5-fluoro-deoxyuridine-5'-monophosphate (5'-FdUMP). In view of the involvement of the nucleotidases catalyzed reactions in the release of erythrocyte-encapsulated pyrimidine pro-drugs, the knowledge of their kinetic and regulatory properties might contribute to modulate drugs delivery rate⁴. The kinetics of PN-I and PN-II were examined by using a broad range of substrates. The homogeneous PN-I catalyzes the dephosphorylation of several pyrimidine nucleoside monophosphates in the order: 5'UMP > 5'CMP > 5'dCMP > 5'dTMP > > 5'dUMP > 5'AZT-MP; p-nitrophenylphosphate was a very poor substrate. The homogeneous PN-II catalyzes the dephosphorylation of several pyrimidine nucleoside monophosphates in the order: 3'dTMP > 3'dUMP > 3'UMP > 5'FdUMP > 2'UMP > 3'GMP > 5'dIMP > 5'UMP > 3'dGMP > 5'IMP > 5'UMP > 2'GMP; p-nitrophenylphosphate was also in this case a very poor substrate. Among a large variety of compounds tested as possible effectors of the two enzymatic activities, only the reaction products exerted an inhibitory action. Kinetic analysis showed that phosphate and nucleosides are competitive and non-competitive inhibitors, respectively, suggesting an Ordered Uni-Bi mechanism for the reaction.

The two enzymes, in the presence of suitable nucleoside substrates, can also act as phosphotransferases, catalyzing the transfer of the phosphate moiety from a nucleoside monophosphate donor to a nucleoside acceptor. The evaluation of the kinetic analysis of the phosphotransferase activity is not straightforward, since the enzymatic proteins simultaneously catalyze both hydrolytic and phosphotransferasic reactions. The results obtained are consistent both with a Ping-Pong and an Ordered Bi Bi mechanism. PN-I phosphotransferase activity revealed higher affinity for oxy- nucleosides with respect to deoxy- nucleosides, whereas the contrary seems to be true for PN-II phosphotransferase associated activity. Among various pyrimidine nucleoside acceptors tested, also 3'-azido-

3'-deoxythymidine (AZT), cytosine- β -D-arabinofuranoside (AraC) and 5-fluoro-2'-deoxyuridine (5FdUrd) were phosphorylated. These results show for the first time that soluble pyrimidine nucleotidases are endowed with pyrimidine-specific phosphotransferase activity. These observations suggest that the two cytoplasmic pyrimidine 5'-nucleotidases operate as interconverting activities, capable of transferring the phosphate from the pyrimidine nucleoside monophosphate donor(s) to various nucleoside acceptors, including important drugs like, pyrimidine analogues widely used in chemotherapy.

REFERENCES

- ¹Hirono, A.; Fujii, H.; Natori, H.; Kurokawa, I.; Miwa, S. *Brit. J. Haematol.*, **1987**, *65*, 35-41.
- ²Amici A.; Emanuelli, M.; Raffaelli, N.; Ruggieri, S.; Magni, G. *Anal. Biochem.*, **1994**, *216*, 171-175.
- ³Amici A.; Emanuelli, M.; Ferretti, E.; Raffaelli, N.; Ruggieri, S.; Magni, G. *Biochem J.*, **1994**, *304*, 987-992.
- ⁴De Flora, A.; Zocchi, E.; Guida, L.; Polvani, C.; Benatti, U. *Proc. Natl. Acad. Sci. USA*, **1988**, *85*, 3145-3149.